GSK343, an Inhibitor of Enhancer of Zeste Homolog 2, Reduces Glioblastoma Progression through Inflammatory Process Modulation: Focus on Canonical and Non-Canonical NF-κB/IκBα Pathways
Authors:
- Sarah Adriana ScuderiSSSarah Adriana Scuderi
- Alessia FilipponeAlessia Filippone
- Rossella BasilottaRBRossella Basilotta
- Deborah ManninoDMDeborah Mannino
- Giovanna CasiliGiovanna Casili
- Anna Paola CapraACAnna Paola Capra
- Giulia ChisariGCGiulia Chisari
- Lorenzo ColarossiLCLorenzo Colarossi
- Serena SavaSSSerena Sava
- Michela CampoloMichela Campolo
- Emanuela EspositoEmanuela Esposito
- Irene PaternitiIPIrene Paterniti
Open Access
- 11 November 2022
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (22) , 13915
Abstract
Glioblastoma (GB) is a tumor of the central nervous system characterized by high proliferation and invasiveness. The standard treatment for GB includes radiotherapy and chemotherapy; however, new therapies are needed. Particular attention was given to the role of histone methyltransferase enhancer of zeste-homolog-2 (EZH2) in GB. Recently, several EZH2-inhibitors have been developed, particularly GSK343 is well-known to regulate apoptosis and autophagy processes; however, its abilities to modulate canonical/non-canonical NF-κB/IκBα pathways or an immune response in GB have not yet been investigated. Therefore, this study investigated for the first time the effect of GSK343 on canonical/non-canonical NF-κB/IκBα pathways and the immune response, by an in vitro, in vivo and ex vivo model of GB. In vitro results demonstrated that GSK343 treatments 1, 10 and 25 μM significantly reduced GB cell viability, showing the modulation of canonical/non-canonical NF-κB/IκBα pathway activation. In vivo GSK343 reduced subcutaneous tumor mass, regulating canonical/non-canonical NF-κB/IκBα pathway activation and the levels of reactive oxygen species (ROS), malondialdehyde (MDA), and superoxide dismutase (SOD). Ex vivo results confirmed the anti-proliferative effect of GSK343 and also demonstrated its ability to regulate immune response through CXCL9, CXCL10 and CXCL11 expression in GB. Thus, GSK343 could represent a therapeutic strategy to counteract GB progression, thanks to its ability to modulate canonical/non-canonical NF-κB/IκBα pathways and immune response.Keywords
This publication has 64 references indexed in Scilit:
- Glioblastoma and Other Malignant GliomasJAMA, 2013
- Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibitionCell Cycle, 2013
- The Definition of Primary and Secondary GlioblastomaClinical Cancer Research, 2013
- Downregulation of Ezh2 expression by RNA interference induces cell cycle arrest in the G0/G1 phase and apoptosis in U87 human glioma cellsOncology Reports, 2012
- The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AMLBlood, 2011
- Context-Specific Regulation of NF-κB Target Gene Expression by EZH2 in Breast CancersMolecular Cell, 2011
- Matrix Metalloproteinases: Regulators of the Tumor MicroenvironmentCell, 2010
- Glioblastoma in adultsCritical Reviews in Oncology/Hematology, 2008
- Dysregulation of apoptotic signaling in cancer: Molecular mechanisms and therapeutic opportunitiesJournal of Cellular Biochemistry, 2008
- A threshold concept for cancer therapyMedical Hypotheses, 2000